- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
M-110P Easily Incorporated into Any Laboratory Setting
MFIC Corporation (OTCBB: MFIC), an industry-leader in high-shear processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries announced today the introduction by its operating subsidiary, Microfluidics Corporation, of the M-110P Microfluidizer laboratory scale processor. The M-110P, the Company's first portable bench top plug and play unit, can easily be incorporated into any laboratory setting because it is powered by only standard 20 amp household electrical current and requires no compressed air or cooling water. These features of the M-110P provide a critical formulation solution to customers who have been unable to test and formulate products in the past because they lacked the onsite systems requirements needed to allow them to operate small air operated laboratory units or the three phase electrical requirements needed to operate larger volume laboratory equipment.
The M-110P was designed to operate reliably, quietly and efficiently through a range of operating pressures from 2,000 psi to 30,000 psi, easily enabling the production of nano-suspensions and nano-emulsions, as well as liposomal encapsulation and cell disruption. Importantly, the M-110P also allows for higher flow rates - between 110-155 ml/minute at any process pressure - than any comparable, competitive product, allowing for the production of more sophisticated products including pharmaceutical formulations, fine chemicals, and biological material ranging from simple oil-in-water emulsions to highly immiscible solids-in-liquid suspensions. All results from the M-110P are guaranteed to be scaleable to pilot and/or production volumes, allowing even the smallest customers the ability to fully develop, test, manufacture and produce their products.
"We think the M-110P will play an important role in our long-term growth strategy," said Robert Bruno, President and Chief Operating Officer of MFIC Corporation. "The introduction of the M-110P continues to position MFIC as the industry leader in providing formulation solutions and allows us to reach out to a larger customer base than we have been able to serve previously."
About MFIC Corporation
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company’s plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company’s Microfluidizer® materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company’s MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company’s stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company’s ability to comply with the covenants and terms of its loan agreement with its senior lender.
For more information, please click here
Jack M. Swig, 617-969-5452
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Chad Mirkin receives nanotechnology prize in Russia October 26th, 2016
Imaging where cancer drugs go in the body could improve treatment October 26th, 2016
Nanosciences: Genes on the rack October 21st, 2016